Friday, July 10, 2026

pharma · Hypertension · Gastric Ulcer

Yung Shin Pharmaceutical

Yung Shin Pharmaceutical clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Taichung, CN HQ
1952 Founded
264 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Taichung, CN
Founded
1952
Employees
264
Programs
10
Drugs
13
Patents
0
Intelligence · Clinical Programs

Yung Shin Pharmaceutical projects

5 ClinicalTrials.gov programs sponsored by Yung Shin Pharmaceutical.

Yung Shin Pharmaceutical has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. BRI-1501

    Yung NA

    Gastric Ulcer

    phase 1 small molecule completed

    1 trial
  2. Fimasartan

    Yung NA

    Essential Hypertension

    phase 1 small molecule completed

    1 trial
  3. Fimasartan

    Yung NA

    Hypertension

    phase 1 small molecule completed

    1 trial
  4. Fimasartan/Atorvastatin Combination Tablet

    Yung NA

    Hypertension

    phase 1 small molecule completed

    1 trial
  5. Rabeprazole Sodium 10mg

    Yung NA

    Gastroesophageal Reflux Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Yung Shin Pharmaceutical have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.